BioSpace News Archive

Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced the launch of MyoCare™, a new program that provides enhanced support to first-year users of the Company’s MyoPro® powered brace in order to maximize the benefits they receive from the device.

Centogene N.V., a commercial-stage diagnostics and genetic research company, announced that its paper ‘Rapid Large-Scale COVID-19 Testing During Shortages’ has been published in Diagnostics, an international peer-reviewed open access journal on medical diagnosis.

Testing of blood-based biomarkers will offer convenient detection and monitoring of disease progression in pre-symptomatic and early Alzheimer’s disease (AD)

Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration has accepted and granted priority review for a new supplemental Biologics License Application for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.

Orchard Therapeutics, a global gene therapy leader, and MolMed S.p.A, one of the company’s principal contract development and manufacturing partners, announced that they have extended their collaboration – initiated in April 2018 – for a period of five years through June 2025.

Company providing BXCL501 to evaluate its activity in patients with COVID-19 that may require calming or arousable sedation following intubation

Dr. William Andrews brings two decades of global industry experience, including more than 13 years in rare diseases and seven product launches

Kymera to receive $150 million upfront with more than $2 billion in potential milestones plus royalty payments

Initiated Phase 1b Study Evaluating EDP-514 in Viremic HBV Patients; Preliminary Data Anticipated in 1H 2021

New funding will drive advancement of a global therapeutic portfolio in oncology and immunology, including monoclonal antibodies for COVID-19 therapeutics and diagnostics